annual meeting program - American Society of Clinical Oncology

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM
PARP Inhibition: DNA Repair as the Target
Location: E Arie Crown Theater
CME credit: 1.5
Track(s): Developmental Therapeutics
Saturday, June 5, 2010
Patrick Johnston, MD, PhD—Co-Chair
Queen’s University Belfast
Eunice Lee Kwak, MD, PhD—Co-Chair
Massachusetts General Hospital
Discussion
4:30 PM Alan Hilary Calvert, MD
Cancer Research Unit
PARP as a Therapeutic Target
4:45 PM Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose)
polymerase (PARP) inhibitor, in combination with cyclophosphamide.
(Abstract #3000)
A. R. Tan, D. Gibbon, M. N. Stein, R. A. Moss, V. Karantza, H. Lin, M. Gounder,
A. P. Chen, M. J. Egorin, R. S. DiPaola
5:00 PM First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor
MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCAdeficient
and sporadic ovarian cancers. (Abstract #3001)
S. K. Sandhu, R. M. Wenham, G. Wilding, M. McFadden, L. Sun, C. Toniatti,
M. Stroh, C. L. Carpenter, J. S. De Bono, W. R. Schelman
5:15 PM Can we define tumors that will respond to PARP inhibitors? A phase II
correlative study of olaparib in advanced serous ovarian cancer and triplenegative
breast cancer. (Abstract #3002)
K. A. Gelmon, H. W. Hirte, A. Robidoux, K. S. Tonkin, M. Tischkowitz,
K. Swenerton, D. Huntsman, J. Carmichael, E. Macpherson, A. M. Oza
Discussion
5:30 PM James H. Doroshow, MD (Abstracts #3000–3002)
National Cancer Institute
State of Development for PARP Inhibition
187
SATURDAY